HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Web-only chart Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kipps, C M Articles by McCusker, E A Search for Related Content PubMed PubMed Citation Articles by Kipps, C M Articles by McCusker, E A Topic Collections Relevant Article

Progression of structural neuropathology in preclinical Huntington’s disease: a tensor based morphometry study

¹ Department of Neurology, Westmead Hospital, Westmead, NSW 2145, Australia
² Department of Radiology, Westmead Hospital, Westmead, NSW 2145, Australia
³ Wellcome Department of Imaging Neuroscience, Institute of Neurology, Queen Square, London WC1N 3BG, UK

Correspondence to:
Correspondence to:
Dr C M Kipps
Neurology Unit, University of Cambridge, R3 Neurosciences, Addenbrooke’s Hospital, Cambridge CB2 2QQ, UK; cmk41{at}medschl.cam.ac.uk

Background and objectives: Regional cerebral atrophy occurs in carriers of the Huntington’s disease (HD) gene mutation before clinical diagnosis is possible. The current inability to reliably measure progression of pathology in this preclinical phase impedes development of therapies to delay clinical onset. We hypothesised that longitudinal statistical imaging would detect progression of structural pathology in preclinical carriers of the HD gene mutation, in the absence of measurable clinical change.

Methods: Thirty subjects (17 preclinical mutation positive, 13 mutation negative) underwent serial clinical and magnetic resonance imaging (MRI) assessments over an interval of 2 years. Statistically significant changes in regional grey and white matter volume on MRI were analysed using tensor based morphometry (TBM). This technique derives a voxel-wise estimation of regional tissue volume change from the deformation field required to warp a subject’s early to late T1 images.

Results: Over 2 years, there was progressive regional grey matter atrophy in mutation-positive relative to negative subjects, without significant clinical progression of disease. Significant grey matter volume loss was limited to bilateral putamen and globus pallidus externa (GPe), left caudate nucleus, and left ventral midbrain in the region of the substantia nigra.

Conclusions: While these results are consistent with previous cross sectional pathologic and morphometric studies, significant progression of atrophy in HD before the onset of significant clinical decline is now demonstrable with longitudinal statistical imaging. Such measures could be used to assess the efficacy of potential disease modifying drugs in slowing the progression of pathology before confirmed clinical onset of HD.

Abbreviations: GM segment, grey matter segment; GPe, globus pallidus externa; HD, Huntington’s disease; MNI, Montreal Neurologic Institute; MRI, magnetic resonance imaging; SNr, substantia nigra pars reticulata; SVC, small volume correction; TBM, tensor based morphometry; UHDRS, United Huntington’s Disease Rating Scale; VBM, voxel based morphometry; WM segment, white matter segment

Keywords: disease progression; Huntington’s disease; longitudinal imaging; tensor based morphometry

Relevant Article

Imaging Huntington’s disease (HD) brains – imagine HD trials!

H P H Kremer
J. Neurol. Neurosurg. Psychiatry 2005 76: 620. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

				R I SCAHILL and N C FOX Longitudinal imaging in dementia Br. J. Radiol., December 1, 2007; 80(Special_Issue_2): S92 - S98. [Abstract] [Full Text] [PDF]

				A. Feigin, C. Tang, Y. Ma, P. Mattis, D. Zgaljardic, M. Guttman, J. S. Paulsen, V. Dhawan, and D. Eidelberg Thalamic metabolism and symptom onset in preclinical Huntington's disease Brain, November 1, 2007; 130(11): 2858 - 2867. [Abstract] [Full Text] [PDF]

				P. Nopoulos, V. A. Magnotta, A. Mikos, H. Paulson, N. C. Andreasen, and J. S. Paulsen Morphology of the Cerebral Cortex in Preclinical Huntington's Disease Am J Psychiatry, September 1, 2007; 164(9): 1428 - 1434. [Abstract] [Full Text] [PDF]

				T. J. Whitford, S. M. Grieve, T. F.D. Farrow, L. Gomes, J. Brennan, A. W.F. Harris, E. Gordon, and L. M. Williams Volumetric White Matter Abnormalities in First-Episode Schizophrenia: A Longitudinal, Tensor-Based Morphometry Study Am J Psychiatry, July 1, 2007; 164(7): 1082 - 1089. [Abstract] [Full Text] [PDF]

				C. M. Kipps, A. J. Duggins, E. A. McCusker, and A. J. Calder Disgust and Happiness Recognition Correlate with Anteroventral Insula and Amygdala Volume Respectively in Preclinical Huntington's Disease. J. Cogn. Neurosci., July 1, 2007; 19(7): 1206 - 1217. [Abstract] [Full Text] [PDF]

				H P H Kremer Imaging Huntington's disease (HD) brains - imagine HD trials! J. Neurol. Neurosurg. Psychiatry, May 1, 2005; 76(5): 620 - 620. [Full Text] [PDF]